Literature DB >> 8547126

The metabolites of nitric oxide in sickle-cell disease.

D C Rees1, P Cervi, D Grimwade, A O'Driscoll, M Hamilton, N E Parker, J B Porter.   

Abstract

Plasma NOx concentrations were raised in 22 acute painful crises in SCD. We have measured blood concentrations of nitric oxide metabolites (NOx) in sickle-cell disease (SCD), and shown that they are increased compared with healthy controls (P = 0.002), and haemoglobin E/beta-thalassaemic controls (P = 0.05). Concentrations in steady-state SCD were also higher than in healthy controls (P = 0.04) but not significantly different from the concentrations at the beginning of painful crises (P = 0.34). Importantly, in 12 regularly exchanged sicklers, the mean pre-transfusion NOx concentration did not differ significantly from the control population (P = 0.52), suggesting that the changes in NO metabolism can be reversed. It is unlikely that the increased concentrations of NOx in SCD result from anaemia or haemolysis as the untransfused haemoglobin E/beta-thalassaemics did not show increased levels.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8547126     DOI: 10.1111/j.1365-2141.1995.tb05397.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  17 in total

1.  Reaping of nitric oxide by sickle cell disease.

Authors:  Jack R Lancaster
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

2.  Overactive bladder in adults with sickle cell disease.

Authors:  Uzoma A Anele; Belinda F Morrison; Marvin E Reid; Wendy Madden; Shara Foster; Arthur L Burnett
Journal:  Neurourol Urodyn       Date:  2015-04-14       Impact factor: 2.696

3.  Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease.

Authors:  M Aslan; T M Ryan; B Adler; T M Townes; D A Parks; J A Thompson; A Tousson; M T Gladwin; R P Patel; M M Tarpey; I Batinic-Haberle; C R White; B A Freeman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

Review 4.  cGMP modulation therapeutics for sickle cell disease.

Authors:  Nicola Conran; Lidiane Torres
Journal:  Exp Biol Med (Maywood)       Date:  2019-01-28

5.  Endothelial activation and inflammation biomarkers in children and adolescents with sickle cell disease.

Authors:  Emmanuil S Hatzipantelis; Zoe Dorothea Pana; N Gombakis; A Taparkou; V Tzimouli; D Kleta; D J Zafeiriou; V Garipidou; F Kanakoudi; M Athanassiou
Journal:  Int J Hematol       Date:  2013-06-27       Impact factor: 2.490

6.  Oral citrulline as arginine precursor may be beneficial in sickle cell disease: early phase two results.

Authors:  W H Waugh; C W Daeschner; B A Files; M E McConnell; S E Strandjord
Journal:  J Natl Med Assoc       Date:  2001-10       Impact factor: 1.798

7.  Simvastatin reduces vaso-occlusive pain in sickle cell anaemia: a pilot efficacy trial.

Authors:  Carolyn Hoppe; Eufemia Jacob; Lori Styles; Frans Kuypers; Sandra Larkin; Elliott Vichinsky
Journal:  Br J Haematol       Date:  2017-03-28       Impact factor: 6.998

8.  Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial.

Authors:  Mark T Gladwin; Gregory J Kato; Debra Weiner; Onyinye C Onyekwere; Carlton Dampier; Lewis Hsu; R Ward Hagar; Thomas Howard; Rachelle Nuss; Maureen M Okam; Carole K Tremonti; Brian Berman; Anthony Villella; Lakshmanan Krishnamurti; Sophie Lanzkron; Oswaldo Castro; Victor R Gordeuk; Wynona A Coles; Marlene Peters-Lawrence; James Nichols; Mary K Hall; Mariana Hildesheim; William C Blackwelder; James Baldassarre; James F Casella
Journal:  JAMA       Date:  2011-03-02       Impact factor: 56.272

9.  Impaired vasodilation by red blood cells in sickle cell disease.

Authors:  John R Pawloski; Douglas T Hess; Jonathan S Stamler
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-07       Impact factor: 11.205

10.  Molecular analysis of erection regulatory factors in sickle cell disease associated priapism in the human penis.

Authors:  Gwen Lagoda; Sena F Sezen; Marcelo R Cabrini; Biljana Musicki; Arthur L Burnett
Journal:  J Urol       Date:  2012-10-08       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.